NKA Bio is developing new medicines to press pause on death and buy more time for life-saving care
About NKA Bio
Who:
NKA Bio is a biotech startup founded based on research by the 1st Director of Emergency Medicine at Johns Hopkins.
What:
NKA Bio is developing new medicines for critically ill patients that press pause on death and buy more time for life saving care.
Where:
NKA Bio operates R&D facilities in Baltimore, Maryland Equipped for Antibody Engineering and Assay Development
When:
NKA Bio's lead drug candidate, NKA01, is on a path to enter the clinic in 18 months.
The Problem
Contrary to popular belief, people don't die from car crashes or gun shots.
People die from their body's response to the injury, a state known as shock.
Shock is the #1 Cause of Death for People Ages 1 - 44 in the United States
Every Year in addition to the 90,000 trauma patients who don't live long enough to get to a hospital...
Our Solution
Introducing NKA01
When minutes count, our antibody buys hours. NKA01 presses pause on death with a low-volume injection at the point of injury to buy more time for transport and lifesaving surgery.
Product:
Prefilled Syringe with our Anti-Shock Toxin Antibody for Injection by EMS during their standard treatment protocols to prepare the patient for transport.
Key Features:
Temperature stable and low volume for field use by EMS to immediately stabilize trauma patients and press pause on death to buy more time for transport to a trauma center for care.
Progress to Date:
Proof of Concept In Vivo with a Prototype. Lead Candidate Selected.
Pipeline
World Health Organization
Team
Shock Pioneer Behind Discovery
(1932 - 2020)
Dr. Gann was a pioneer and leader in trauma care and biomedical engineering, serving as the first Director of Emergency Medicine at Johns Hopkins and the first Chair of Biomedical Engineering at Case Western Reserve. A polymath with a background in physics, philosophy, and medicine, Dr. Gann's research was continuously funded by the NIH to study the body's response to hemorrhage.
Donald S. Gann, MD
Susan Gann Hibbs
Chief Executive Officer
Corporate Vision
Investor Relations
Corporate Operations
Lewis C. Hibbs III
Chief Technology Officer
R&D Lead
In Silico Platform Development
Research & Grant Writing
Les E. Johnson
Regulatory Lead
CMC Expert
Quality & Risk Management
